These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36412252)

  • 21. The Renin-Angiotensin-Aldosterone System in Greyhounds and Non-Greyhound Dogs.
    Martinez J; Kellogg C; Iazbik MC; Couto CG; Pressler BM; Hoepf TM; Radin MJ
    J Vet Intern Med; 2017 Jul; 31(4):988-993. PubMed ID: 28488321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pressor and hormonal responses to angiotensin I infusion in healthy subjects of different angiotensin-converting enzyme genotypes.
    Chadwick IG; O'Toole L; Morice AH; Yeo WW; Jackson PR; Ramsay LE
    J Cardiovasc Pharmacol; 1997 Apr; 29(4):485-9. PubMed ID: 9156358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
    Sama IE; Ravera A; Santema BT; van Goor H; Ter Maaten JM; Cleland JGF; Rienstra M; Friedrich AW; Samani NJ; Ng LL; Dickstein K; Lang CC; Filippatos G; Anker SD; Ponikowski P; Metra M; van Veldhuisen DJ; Voors AA
    Eur Heart J; 2020 May; 41(19):1810-1817. PubMed ID: 32388565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronobiology and Pharmacologic Modulation of the Renin-Angiotensin-Aldosterone System in Dogs: What Have We Learned?
    Mochel JP; Danhof M
    Rev Physiol Biochem Pharmacol; 2015; 169():43-69. PubMed ID: 26428686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma and tissue angiotensin-converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease.
    Larouche-Lebel É; Loughran KA; Oyama MA; Solter PF; Laughlin DS; Sánchez MD; Assenmacher CA; Fox PR; Fries RC
    J Vet Intern Med; 2019 Jul; 33(4):1571-1584. PubMed ID: 31254308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The renin-angiotensin-aldosterone system, neurohumoral axis and cardiovascular mortality in LURIC.
    Yazdani B; Delgado GE; Kleber ME; Yücel G; Husain-Syed F; Kraemer TD; Jochims J; Leipe J; März W; Krämer BK
    J Clin Hypertens (Greenwich); 2022 Dec; 24(12):1587-1597. PubMed ID: 36349861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The renin-angiotensin-aldosterone system and heart failure.
    Sayer G; Bhat G
    Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Ramipril on the Aldosterone/Renin Ratio and the Aldosterone/Angiotensin II Ratio in Patients With Primary Aldosteronism.
    Guo Z; Poglitsch M; Cowley D; Domenig O; McWhinney BC; Ungerer JPJ; Wolley M; Stowasser M
    Hypertension; 2020 Aug; 76(2):488-496. PubMed ID: 32507039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype.
    Cicoira M; Zanolla L; Rossi A; Golia G; Franceschini L; Cabrini G; Bonizzato A; Graziani M; Anker SD; Coats AJ; Zardini P
    J Am Coll Cardiol; 2001 Jun; 37(7):1808-12. PubMed ID: 11401115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations of central and peripheral blood pressure with the renin-angiotensin-aldosterone system in healthy young adults: the African-PREDICT study.
    Gafane-Matemane LF; Mokae NL; Breet Y; Poglitsch M; Schutte AE
    Hypertens Res; 2021 Apr; 44(4):435-445. PubMed ID: 33122821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H; Gilbert RE
    J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dynamic changes of renin-angiotensin-aldosterone system parameters after surgery of primary hyperparathyroidism].
    Dobreva EA; Bibik EE; Eremkina AK; Ajnetdinova AR; Nikankina LV; Malysheva NM; Mokrysheva NG
    Ter Arkh; 2020 Nov; 92(10):63-69. PubMed ID: 33346481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Renin Angiotensin Aldosterone System Genes in Diabetic Nephropathy.
    Rahimi Z
    Can J Diabetes; 2016 Apr; 40(2):178-83. PubMed ID: 26619914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of renin-angiotensin-aldosterone system-blocking drugs on peritoneal membrane in peritoneal dialysis patients.
    Trošt Rupnik A; Pajek J; Guček A; Osredkar J; Kovač D; Bren A; Klančič D; Saksida S; Rus I; Globokar M; Drozg A; Lešnik M; Plešivčnik Z; Ekart R; Lopert S; Lindič J
    Ther Apher Dial; 2013 Aug; 17(4):425-30. PubMed ID: 23931884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs.
    Ames MK; Atkins CE; Lee S; Lantis AC; zumBrunnen JR
    Am J Vet Res; 2015 Dec; 76(12):1041-50. PubMed ID: 26618728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats.
    Hamming I; van Goor H; Turner AJ; Rushworth CA; Michaud AA; Corvol P; Navis G
    Exp Physiol; 2008 May; 93(5):631-8. PubMed ID: 18192334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis.
    Dörr K; Kammer M; Reindl-Schwaighofer R; Lorenz M; Marculescu R; Poglitsch M; Beitzke D; Oberbauer R
    Front Med (Lausanne); 2022; 9():878730. PubMed ID: 35559350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
    Ferrario CM
    Life Sci; 2010 Feb; 86(9-10):289-99. PubMed ID: 19958778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.